IRIS
MAIO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.594
EU - Europa 13.991
AS - Asia 11.806
SA - Sud America 3.820
AF - Africa 489
OC - Oceania 54
Continente sconosciuto - Info sul continente non disponibili 11
Totale 52.765
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.184
SG - Singapore 4.509
RU - Federazione Russa 3.528
BR - Brasile 3.157
IE - Irlanda 2.513
CN - Cina 2.473
GB - Regno Unito 2.032
VN - Vietnam 1.924
IT - Italia 1.792
FR - Francia 1.300
HK - Hong Kong 1.159
UA - Ucraina 785
SE - Svezia 611
DE - Germania 476
BD - Bangladesh 371
FI - Finlandia 295
IN - India 291
AR - Argentina 245
ZA - Sudafrica 242
KR - Corea 237
ES - Italia 184
CA - Canada 162
MX - Messico 127
EC - Ecuador 126
NL - Olanda 123
ID - Indonesia 111
IQ - Iraq 107
AT - Austria 78
TR - Turchia 73
CO - Colombia 70
JP - Giappone 62
SA - Arabia Saudita 55
PK - Pakistan 54
VE - Venezuela 54
CL - Cile 51
AU - Australia 50
PY - Paraguay 48
PL - Polonia 47
KE - Kenya 39
UZ - Uzbekistan 39
MA - Marocco 38
AE - Emirati Arabi Uniti 33
AZ - Azerbaigian 31
EG - Egitto 31
MY - Malesia 31
NG - Nigeria 30
TN - Tunisia 30
UY - Uruguay 27
DZ - Algeria 26
CZ - Repubblica Ceca 25
PE - Perù 24
JM - Giamaica 23
NP - Nepal 23
IL - Israele 21
LT - Lituania 21
KZ - Kazakistan 20
AL - Albania 18
BE - Belgio 18
CH - Svizzera 18
JO - Giordania 18
PA - Panama 18
BO - Bolivia 17
DO - Repubblica Dominicana 15
OM - Oman 15
PH - Filippine 15
PT - Portogallo 15
BG - Bulgaria 14
GR - Grecia 14
IR - Iran 14
LB - Libano 14
HN - Honduras 13
CI - Costa d'Avorio 12
KG - Kirghizistan 12
ET - Etiopia 11
TW - Taiwan 11
CR - Costa Rica 10
SK - Slovacchia (Repubblica Slovacca) 10
XK - ???statistics.table.value.countryCode.XK??? 10
AM - Armenia 9
BH - Bahrain 9
HU - Ungheria 9
NO - Norvegia 9
TH - Thailandia 9
BY - Bielorussia 8
DK - Danimarca 8
KW - Kuwait 8
LV - Lettonia 8
NI - Nicaragua 8
PS - Palestinian Territory 8
KH - Cambogia 7
RO - Romania 7
SV - El Salvador 7
TT - Trinidad e Tobago 7
AO - Angola 6
LK - Sri Lanka 6
SN - Senegal 6
SY - Repubblica araba siriana 6
BA - Bosnia-Erzegovina 5
BB - Barbados 5
EE - Estonia 5
Totale 52.690
Salva come PNG Salva come JPEG
Città #
Fairfield 3.013
Dallas 2.907
Dublin 2.509
Singapore 2.073
Ashburn 1.711
Southend 1.630
Woodbridge 1.444
Wilmington 1.138
Seattle 1.135
Hong Kong 1.125
Houston 1.119
Cambridge 1.038
Moscow 913
Beijing 842
San Jose 782
Jacksonville 754
Santa Clara 738
Ho Chi Minh City 612
Princeton 533
Siena 412
Lauterbourg 409
The Dalles 402
Ann Arbor 400
Hefei 368
Hanoi 366
San Mateo 358
Los Angeles 296
Dong Ket 280
New York 269
São Paulo 247
Helsinki 235
Seoul 218
Council Bluffs 201
Dearborn 198
San Diego 197
Johannesburg 189
Milan 189
Chandler 168
Buffalo 143
Redondo Beach 134
Málaga 130
Florence 126
Shanghai 122
Rome 108
London 99
Rio de Janeiro 94
Nuremberg 90
Amsterdam 77
San Francisco 76
Da Nang 74
Orem 74
Chicago 71
Munich 63
Haiphong 62
Brasília 58
Belo Horizonte 56
Tokyo 56
Salvador 55
Dhaka 54
Frankfurt am Main 52
Curitiba 51
Phoenix 51
Toronto 51
Brooklyn 50
Bengaluru 48
Guayaquil 47
Nanjing 47
Delhi 44
Stockholm 44
Chennai 43
Denver 43
Guangzhou 43
Montreal 43
Porto Alegre 43
Campinas 42
Norwalk 41
Vienna 41
Boardman 40
Guarulhos 40
Lappeenranta 36
Tashkent 36
Warsaw 35
Baghdad 33
Quito 33
Goiânia 32
Manchester 31
Buenos Aires 30
Hải Dương 30
Mexico City 30
Portsmouth 30
Riyadh 30
Thái Bình 30
Ninh Bình 29
Atlanta 27
Baku 27
Biên Hòa 27
Naples 27
Boston 26
Fortaleza 26
Abuja 25
Totale 34.774
Salva come PNG Salva come JPEG
Nome #
Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team 501
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 346
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 329
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 318
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade 283
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 261
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 261
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 249
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 248
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 244
Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors 243
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 241
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial 240
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 239
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 227
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 225
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches 224
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 224
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 222
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy 222
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 222
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. 218
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 212
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy 212
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours 211
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 209
Back to simplicity: A four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 209
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 208
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 206
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 205
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 203
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients 198
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 197
Biomolecular strategies for therapeutic intervention in cancer 196
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial 196
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 194
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 193
Biology and clinical applications of CD40 in cancer treatment 192
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 190
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability 190
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 190
The biology of cancer testis antigens: putative function, regulation and therapeutic potential 189
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 188
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 187
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893 186
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma 186
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 185
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 184
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study 184
A novel microRNA signature for the detection of melanoma by liquid biopsy 183
Epigenetically-regulated Tumor-Associated Antigens in melanoma 183
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 181
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 178
Immunotherapy targeting immune check-point(s) in brain metastases 175
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 174
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" 174
Perspectives on the role of “-Omics” in predicting response to immunotherapy 172
5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? 172
Active immunization of melanoma patients with IL-2-transfected allogeneic melanoma cells. A phase I-II study 172
5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story 172
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide 171
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial 171
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 170
Active immunization of melanoma patients with IL-2- or IL-4-transduced allogeneic melanoma cells 170
Predictors of responses to immune checkpoint blockade in advanced melanoma 170
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy 170
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma 169
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study 169
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab 169
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 168
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 167
Epigenetic drugs as immunomodulators for combination therapies in solid tumors 165
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 164
CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells 163
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications 163
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 162
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 162
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab 162
The role of BRAF V600 mutation in melanoma 160
Adjuncts in diagnosis, prognosis, and clinical monitoring of breast, gynecologic, and hematolymphopoietic malignancies: Third Joint International Workshop, Lacco Ameno d'Ischia, Italy, October 2001 160
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 160
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study. 160
Effects of cyclophosphamide and IL-2 on regulatory CD4(+) T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response 159
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications 159
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients 158
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients 158
Future perspectives in melanoma research. Meeting report from the “Melanoma research: a bridge from Naples to the world. Napoli, December 5th-6th 2011” 158
Implementing liquid biopsies into clinical decision making for cancer immunotherapy 158
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) 157
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody 157
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 156
5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: Extended follow-up of the coBRIM study 156
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells 156
Whole genome methylation profiles as independent markers of survival in stage IIIc melanoma patients 155
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009 155
Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications 155
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? 154
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? 154
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010" 154
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 153
Totale 19.480
Salva come PNG Salva come JPEG
Categoria #
all - tutte 196.822
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 196.822
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021588 0 0 0 0 0 0 0 0 0 0 0 588
2021/20223.530 179 419 383 96 44 160 121 153 223 523 373 856
2022/20233.127 408 171 642 400 76 694 85 122 156 142 170 61
2023/20243.538 92 77 268 87 83 1.001 1.212 110 62 37 64 445
2024/20258.424 336 378 445 478 749 325 115 298 948 1.039 1.110 2.203
2025/202620.906 1.480 3.022 2.569 3.315 3.562 646 2.286 780 765 1.072 856 553
Totale 54.004